Company / PP&E (Net)
Boston Scientific PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$4.0B
FY2025
5-year range
$2.3B / $4.0B
FY2021-FY2025
Trend
+22.5%
vs FY2024
Sector context
#12 of 132
Health Care
What the data says
Among 132 Health Care companies, Boston Scientific is in the top 9% for pp&e (net). PP&E (Net) has increased for 5 consecutive years, from $2.1B in FY2020 to $4.0B in FY2025.
Based on SEC 10-K filings.
$4.0B in FY2025 with a 5-year CAGR of +14.2%. Top quartile in the Health Care sector.
Improved from $2.9B to $4.0B over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +18.2%
- 5-Year CAGR
- +14.2%
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 132This company $4.0B Sector average $1.4B
▼
+181.3% above sector average
Key checks
Key Insights
- Boston Scientific's pp&e (net) has grown for 5 consecutive years.
- 5-year CAGR of +14.2%, indicating consistent growth.
- In FY2025, pp&e (net) increased 22.5% year-over-year.
- Ranks #12 out of 132 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.0B | +22.5% |
| FY2024 | $3.3B | +15.2% |
| FY2023 | $2.9B | +16.9% |
| FY2022 | $2.4B | +8.6% |
| FY2021 | $2.3B | +8.3% |
| FY2020 | $2.1B | +0.0% |
| FY2019 | $2.1B | +16.7% |
| FY2018 | $1.8B | +5.0% |
| FY2017 | $1.7B | +4.1% |
| FY2016 | $1.6B | +9.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026